The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo
Leuk Res. 2011 Mar;35(3):373-9. doi: 10.1016/j.leukres.2010.06.026. Epub 2010 Jul 21. Sanchez E, Shen J, Steinberg…
read moreKyphon® Balloon Kyphoplasty Found Beneficial for Treating Spinal Fractures in Cancer Patients
The results of this landmark study should be welcomed news to cancer patients across the…
read moreCounterpoints: To Transplant or Not To Transplant
More Is Not Better Claudia Andreu-Vieyra, Ph.D and James Berenson, M.D. Multiple myeloma (MM) is…
read moreMultiple Myeloma: ‘Old Rules’ No Longer Apply
Original Article Writen by: Robert Carlson – Oncology Times NEW YORK—Treatment regimens for relapsed/refractory multiple…
read moreAn Overview of Progress in Myeloma Research with Dr. James Berenson
Myeloma news from the 2014 annual meeting of the American Society of Clinical Oncology has…
read moreASCO 2014: Results of the dose-escalation portion of a phase 1/2 study (CHAMPION-1) investigating weekly carfilzomib in combination with dexamethasone for patients with relapsed or refractory multiple myeloma
Abstract No: 8594 Background: Carfilzomib (CFZ) is a selective proteasome inhibitor approved in the US…
read moreTommy Garceau, IMBCR’s Marathon Team Captain
Tommy, who has been Dr. Berenson’s able assistant for many years, has a passion for…
read moreTalking About Myeloma with Loved Ones
Do you feel the Love? The New Year is here. Perhaps you have been newly…
read moreCounterpoints: Do Patients With Multiple Myeloma Need Maintenance Treatment?
By Clinical Advances in Hematology & Oncology March 2015, Volume 13, Issue 3 Multiple myeloma…
read moreKIIS Cares Interview
What: Myeloma is a disease in your bone marrow. Inside your bone marrow are the…
read more